Suven Life Sciences has received an approval to create an overseas subsidiary with an initial investment of $25 million for clinical development and commercialization of Suven pipeline and in-licensed molecules. The board of directors at their meeting held on August 14, 2015 has approved for the same.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.
